Aim: Recent evidence suggests that small dense low-density lipoprotein (sd-LDL) particles are more atherogenic than large-LDL in spite of their lower cholesterol content. This study aimed to determine whether sd-LDL-cholesterol (sd-LDL-C) is superior to LDL-C as a biomarker of coronary heart disease (CHD). Methods: LDL particle size determined by gradient gel electrophoresis and sd-LDL-C concentrations quantified by heparin-magnesium precipitation were compared between 482 stable CHD patients and 389 non-diabetic subjects without CHD who were not receiving any lipid-lowering drugs. Results: Both male and female CHD patients had significantly smaller LDL particles and lower large-LDL-C concentrations (estimated by subtracting the sd-LDL-C concentration from the LDL-C concentration), and significantly higher sd-LDL-C concentrations than the control subjects. LDL-C concentrations were modestly higher and sd-LDL-C concentrations were significantly higher in 258 patients with angiographically documented severe CHD than in the patients with mild CHD irrespective of treatment by LDL-lowering drugs and history of myocardial infarction and/or coronary revascularization. Large-LDL-C concentrations, in contrast, were similar between the two groups. Multivariate logistic regression analysis revealed that sd-LDL-C levels were significantly associated with severe CHD independently of LDL-C. Conclusion: sd-LDL-C levels are more powerful than LDL-C levels for the determination of severe stable CHD. 
Introduction
Reducing the concentration of low-density lipoprotein cholesterol (LDL-C) in serum is the primary target for the prevention of coronary heart disease (CHD) under current national and international guidelines [1] [2] [3] . Among patients with established CHD, the resistance to oxidative stress compared to large-LDL 6, 7) . The Québec cardiovascular study has confirmed that a greater proportion of sd-LDL at baseline is a strong and independent predictor of CHD in the first 7 years of follow-up 8) . In contrast, an elevated concentration of large-LDL is a poor predictor of CHD and seems to be associated with a low CHD risk 8) . This suggests that the atherogenicity of LDL differs among heterogeneous LDL particles and that the association of atherogenic LDL-C with CHD is chiefly due to the sd-LDL component.
Our group recently discovered a simple and rapid method for measuring selectively the cholesterol content of the sd-LDL fraction by heparin magnesium precipitation [9] [10] [11] . We recently found that a high sd-LDL-C concentration evaluated by this precipitation method was closely related to the angiographical and/or clinical severity of CHD independently of classical coronary risk factors, whereas the large-LDL-C concentration was generally comparable among various types of CHD patients untreated by lipid-lowering drugs 12) . On the basis of this evidence, sd-LDL particles seem likely to be major atherogenic components of LDLs. The aims of this study were to determine whether sd-LDL-C is superior to LDL-C and/ or non-lipid biomarkers of CHD progression such as high-sensitivity C-reactive protein (hs-CRP) among healthy non-CHD subjects and stable CHD subjects treated and untreated with lipid-lowering drugs.
Methods

Subjects
The study enrolled 482 consecutive previously diagnosed CHD patients who underwent coronary arteriography at our hospital from April 2004 to September 2005 and 389 non-CHD control subjects. The non-CHD controls were free from diabetes, were free from any form of cardiovascular disease (including cerebral and peripheral vascular disease) evaluated by a negative exercise electrocardiographic test, had no carotid plaques on ultrasound, and ankle-brachial pressure index 1.0 using a volume-plethysmographic apparatus), and did not receive lipid-lowering drugs. Exclusion criteria included an age of 90 years or older, a prior history of coronary-artery bypass surgery, acute coronary syndrome during 3 months before the study, and all of the following conditions: vasospastic angina, severe congestive heart failure, severe hepatic disease, nephrotic syndrome or renal dysfunction (blood creatinine 1.5 mg/dL), infectious disease, malignancy, and any other serious condition. Data from repeated angiograms for the same patients and data on patients who took drugs for thyroid dysfunction were also excluded. The diagnoses of CHDs such as myocardial infarction (MI) and angina pectoris were based on clinical symptoms, electrocardiographic changes, stress myocardial perfusion scintigraphy, previous coronary arteriograms, and a prior history of percutaneous coronary intervention (PCI). The CHD group consisted of patients with previous MI (238 men and 50 women) and stable angina pectoris (216 men and 55 women) with (n 77) and without (n 194) prior MI. Two hundred and eighty male patients and 58 female patients had previously undergone the PCI. The diagnosis of hypertension was based on a history of hypertension or blood pressure above 140 mmHg systolic or 90 mmHg diastolic. Diabetes mellitus was diagnosed as a fasting serum glucose value greater than 126 mg/dL, hemoglobin (Hb) A1c levels greater than 6.5%, or treatment with either oral hypoglycemic agents or insulin. The institutional review board of Showa University approved this protocol. The investigation conformed to the principles of the Declaration of Helsinki.
Lipoprotein, Metabolic, and Inflammatory Parameter Analysis
The fasting blood samples were obtained by venipuncture and the serum was stored at 4 and used for the assay within 3 days after sampling. Total-cholesterol, triglyceride, high density lipoprotein-cholesterol (HDL-C), HbA1c, immunoreactive insulin (IRI), and Lp(a) levels were measured by standard laboratory procedures. Serum apolipoprotein concentrations were determined by an immunoturbidometric assay (Daiichi Chemicals Co. Tokyo, Japan). The LDL-C concentration was measured by direct homogenous assay of serum using detergents (LDL-EX, Denka Seiken, Tokyo, Japan) 13) . The peak LDL particle diameter was determined by 2-16% non-denatured polyacrylamide gel electrophoresis according to the method of Nichols, et al. 14) . The sd-LDL phenotype was defined as a diameter equal to or less than 255 Å 7) . The sd-LDL-C concentration was measured by rapid assay using a modified version of the heparin-magnesium precipitation method described previously 11) . Having found a strong correlation between cholesterol concentrations and apo-B concentrations in the sd-LDL fraction (r 0.944, p 0.0001) and between cholesterol and apo-B concentrations in the sd-LDL fraction by this precipitation method and in the dense LDL fraction (density 1.044-1.063) by ultracentrifugation (r 0.884, p 0.0001 and r 0.896, p 0.0001, respectively), we speculated that the measurement of sd-LDL-C would be sufficient to evaluate sd-LDL particle number, that is, sd-LDL mass 9) . The hs-CRP concentration was measured by the Dade Behring BN assay 15) . The large-LDL-C concentration was estimated by subtracting the sd-LDL-C concentration from the LDL-C concentration. Our group has previously shown that the large-LDL-C values estimated by this method correlated with values actually determined by ultracentrifugation (r 0.858, p 0.0001) 9) . The non-HDL-C concentration was estimated by subtracting the HDL-C concentration from the total-cholesterol concentration.
Definition of Severe CHD and the Severity of Coronary Atherosclerosis
The severity of coronary atherosclerosis was estimated by calculating the Gensini score, an established method for grading the severity of CHD 16) . Severe CHD was defined as stenosis with more than 50% narrowing of the diameter of the left main coronary artery or more than 75% narrowing of one or more branches of the coronary arteries.
Statistics
Statistical analyses were completed using Statview 5.0 (SAS Institute, Cavy, NC). Comparisons among the control groups and subgroups of CHD based on the presence of lipid-lowering drugs were performed by one way ANOVA. The Bonferroni/Dunn post-hoc test was used when a significant group effect was observed. Comparisons of mean values between the two groups were performed with Student's t -test. Correlation coefficients between two variable parameters were determined by Pearson's simple linear regression analysis. The difference in frequency data was determined by the Chi-squared test. Statistical significance was accepted at p 0.05. A logistic regression analysis was used to assess the independent association between classical risk factors and/or serum markers and the incidence of severe CHD among CHD patients. All variables which were significant in the univariate logistic regression analysis were included in the multivariate logistic regression analysis. Fig. 1 compare the general characteristics and serum lipid markers between the control subjects and CHD patients treated and untreated with lipid-lowering drugs (data for both sexes shown). Twohundred and three male and 60 female patients were treated with lipid-lowering drugs. LDL-C levels were similar between the controls and the untreated CHD patients, and were significantly lower in the treated CHD patients than in the controls and the un-medicated CHD patients of both sexes. Large-LDL-C levels were significantly lower in the untreated CHD patients and were further lower in the treated CHD patients than in the controls. On the other hand, sd-LDL-C levels were significantly higher in both the treated and untreated CHD patients than in the controls in men and were significantly higher in the untreated CHD patients than in the controls in women. The LDL particle size and HDL-C levels were significantly lower in the CHD patients than in the controls of both sexes, irrespective of the presence of lipid-lowering drugs. Although CHD patients were significantly older than non-CHD subjects in both sexes, a correlation between age and sd-LDL-C levels was observed in only non-CHD women (r 0.169, p 0.0307). No such correlation was seen in other groups. Table 2 compares general and metabolic characteristics between mild and severe CHD separately for men and women. The only lipid parameters to differ between genders were HDL-C and apo A-1. Past histories of MI and PCI were significantly less frequent in the severe cases than in the mild cases. In our samesex comparisons between severe CHD and mild CHD, both men and women with severe CHD exhibited significantly higher levels of HbA1c, sd-LDL-C, and apo B, significantly higher Gensini scores, and significantly lower levels of HDL-C and apo A-1. LDL-C, non-HDL-C, and triglyceride levels were significantly higher in severe-CHD men than in mild-CHD men. On the other hand, large-LDL-C and LDL particle size were similar between the two groups. hs-CRP values were slightly higher in the severe-CHD patients of both sexes, but these differences were not statistically significant. Fig. 2 shows the comparison of LDL-C, sd-LDL-C, large-LDL-C, and HDL-C in patients divided into four groups based on the severity of CHD and the presence of lipid-lowering drugs. Patients with severe CHD exhibited significantly higher levels of LDL-C and sd-LDL-C, significantly lower levels of HDL-C and similar levels of large-LDL-C, irrespective of the presence of lipid-lowering drugs. The increases of LDL-C levels in the severe CHD patients compared with the mild CHD patients were chiefly due to those of sd-LDL-C levels. In addition, sd-LDL-C levels were significantly higher in the treated severe-CHD patients than in untreated mild-CHD patients, whereas the LDL-C levels were similar and the large-LDL-C levels were somewhat higher in Comparison of LDL-C, sd-LDL-C, large-LDL-C, and HDL-C levels among control subjects, and treated and untreated CHD patients in men and women.
Results
Table 1 and
Comparison of sd-LDL-Cholesterol and the Presence or Absence of Lipid-Lowering Drugs
All these lipid levels were significantly different among the three groups by ANOVA. Data are expressed as the mean minus standard error. vs the same sex control subjects, vs the same sex CHD patients treated with lipid-lowering drugs p 0.0167 by the Bonferroni/Dunn post-hoc test. unmedicated mild-CHD patients than in medicated severe-CHD patients. Among 263 patients on lipidlowering drugs, 169 males and 53 females took statins alone, 23 males and 4 females took other lipid-lowering drugs such as fibrates and eicosapentaenoic acid, and 11 males and 3 females were treated with a combination of statins and other lipid-lowering drugs. Fig. 3 shows the comparison of LDL-C, sd-LDL-C, large-LDL-C, and HDL-C levels between mild and severe CHD among patient treated with statins, patients treated with lipid-lowering agents other than statins, and untreated patients. Patients with severe CHD exhibited significantly higher levels of LDL-C and sd-LDL-C, significantly lower levels of HDL-C, and similar levels of large-LDL-C, irrespective of the lipid-lowering medication.
sd-LDL-Cholesterol in Association with a Reduction in the LDL-C Concentration
The Adult Treatment of Panel of the National Cholesterol Education Program 1) and the Japanese Atherosclerosis Association 3) have recommended a targeted LDL-C level of less than 100 mg/dL (2.6 mmol/L) for the management of CHD. Thirty-two percent of CHD patients (124 males and 31 females) achieved LDL-C levels of less than 100 mg/dL, and the incidence of severe CHD was significantly lower in those patients (45% vs 58%, p 0.0052). Fig. 4 compares the LDL-C, sd-LDL-C, large-LDL-C, and HDL-C levels between mild and severe CHD separately for the achievement of a reduction in the LDL-C concentration. Among the patients with lower LDL-C levels, sd-LDL-C levels were slightly higher in severe CHD than in mild CHD, but not to a statistically significant extent. Among the patients with a LDL-C level ≥ 100 mg/dL, LDL-C and sd-LDL-C levels were significantly higher in severe CHD than in mild CHD whereas the large-LDL-C levels were similar between the two groups. The differences of LDL-C levels between the mild and severe CHD patients were due to those of sd-LDL-C levels. Fig. 5 compares the LDL-C, sd-LDL-C, large-LDL-C, and HDL-C levels between the mild and severe CHD patients divided into two groups based on prior histories of MI and/or PCI. Patients with severe CHD exhibited significantly higher levels of LDL-C and sd-LDL-C, significantly lower levels of HDL-C, and similar levels of large-LDL-C, irrespective of their histories of MI and PCI. HDL-C concentration. Table 3 shows the results of a logistic regression analysis for determining the severity of CHD among 482 CHD patients. According to a multivariate logistic regression analysis to compare sd-LDL-C with other potent risk factors, an elevated sd-LDL-C concentration was significantly associated with severe CHD independently of the levels of LDL-C, HDL-C, apo A-1, apo B, non-HDL-C, and HbA1c in the stable CHD patients overall and in the CHD patients not treated with lipid-lowering drugs.
sd-LDL-Cholesterol in Association with a Prior History of MI and/or PCI
Discussion
LDL subclasses other than LDL-C have been established as very important markers for predicting CHD risk 7, 8, 17, 18) . Even so, the measurement of LDL
subclasses has yet to be extensively applied in general clinical practice. The present study using a simple method for the direct measurement of sd-LDL-C produced two new and significant findings on LDL subclasses: first, CHD patients showed significantly higher sd-LDL-C levels than control subjects, irrespective of treatment with lipid-lowering drugs, although CHD patients on lipid-lowering drugs showed significantly lower concentrations of LDL-C and large-LDL-C than control men and women; second, the increases of LDL-C levels in the stable CHD patients with severe coronary atherosclerosis compared with the patients without severe coronary atherosclerosis were chiefly due to those of sd-LDL-C levels, irrespective of lipid lowering drugs and a prior history of MI or PCI. This finding supports our preliminary study of CHD 12) , which showed that 65 stable CHD patients requiring coronary revascularization exhibited significantly high concentrations of sd-LDL-C, but not large-LDL-C compared with 58 stable CHD patients who did not need coronary revacularization.
The present results suggest the sd-LDL-C concentration to be a better surrogate marker than the LDL-C concentration for determining the severity of CHD. These results are well consistent with the recent Québec cardiovascular study which has confirmed that a predominance of sd-LDL is a strong and independent predictor of CHD in the first 7 years of follow-up, and that elevated concentrations of large-LDL particles have a more favorable cardiovascular risk profile than lower concentrations of large-LDL particles 8) . In addition, the Framingham Heart Study using nuclear magnetic resonance (NMR) analysis demonstrated that subjects without any components of metabolic syndrome showed significantly higher concentrations of large-LDL particles than sd-LDL particles, in contrast, subjects with metabolic syndrome, a high risk population for CHD, showed significantly higher concentrations of sd-LDL particles than large-LDL particles 19) . Thus, sd-LDL and large-LDL play different roles in atherogenic dyslipidemia, and CHD patients especially those with severe CHD have high concentrations of sd-LDL-C and similar or somewhat low concentrations of large-LDL-C compared with non-CHD subjects and CHD patients without severe coronary atherosclerosis. However, the present results do not provide evidence that large-LDL particles are not atherogenic. The LDL-C levels were strongly associated with both large-LDL-C and sd-LDL-C levels, and large-LDL-C and sd-LDL-C concentrations were higher in cases of severe CHD than mild CHD among untreated patients and among patients without a prior history of MI or PCI. A recent cross-sectional study of healthy individuals as part of the Multi-Ethnic Study of Atherosclerosis (MESA) using NMR spectroscopy 20) showed that not large LDL but small LDL particle concentration and small LDL size were strongly associated with carotid intima-media thickness, a measure of subclinical atherosclerosis. However, they showed that an increase in large LDL particle concentration was significantly associated with intima-media thickness when individuals were classified based on a low or high concentration of small LDL, or the large LDL levels were adjusted for other lipoproteins 20) . The relationship of cholesterol-rich and triglyceride-rich lipoproteins with the progression and severity of CHD has been controversial [21] [22] [23] [24] [25] [26] . Our preliminary study was the first to demonstrate changes in sd-LDL mass in relation to increased severity determined with coronary scoring systems 12) . The present study confirmed this preliminary result in large population of stable CHD patients. The study also compared LDL-C, sd-LDL-C, non-HDL-C, and apo B to determine which were more closely associated with severe CHD. Non-HDL-C and apo B were reported to be more predictive of CHD events than LDL-C, particularly among patients with elevated triglyceride levels, in the Adult Treatment of Panel 1) . In addition, case-control studies have shown that non-HDL-C and apo B are both stronger predictors of CHD than is LDL-C 27, 28) . Furthermore, the prospective AMORIS (Apolipoprotein-related mortality risk) study demonstrated that apo B and apo A-1 levels rather than calculated LDL-C and calculated HDL-C concentrations are strongly related to increased risk of fatal myocardial infarction 29) . To date, no studies have compared directly LDL-C, sd-LDL-C, non-HDL-C and apo B as determinants of severe CHD among CHD patients. Our study, on the other hand, identified sd-LDL-C as the most powerful determinant of severe CHD, independently of LDL-C, non-HDL-C and apo B. The present study showed that neither LDL-C nor large-LDL-C but sd-LDL-C was strongly correlated with HDL-C, another powerful risk factor for CHD. Furthermore, the strong associations of sd-LDL-C with LDL-C, apo B and triglyceride, suggest that high levels of sd-LDL-C correlate with both atherogenic LDL and metabolic dyslipidemia such as increased triglyceride-rich lipoproteins and decreased HDL-C.
Recent studies using the same direct measurement of sd-LDL-C have shown that statins reduce similarly both large-LDL-C and sd-LDL-C 30, 31) . The present study showed significantly higher levels of sd-LDL-C in the treated cases of severe CHD than untreated mild cases of CHD in spite of similar LDL-C levels (114 mg/dL). This suggests that intensive LDL-C lowering therapy should be done in severe cases of CHD in order to achieve a sufficient reduction in levels of sd-LDL-C. Future prospective studies will need to evaluate the effects of intensive lipid-lowering treatment on the reduction in concentration of sd-LDL-C and the secondary prevention of CHD.
Recent prospective studies have shown that elevated levels of hs-CRP at baseline are associated with an increased risk of onset and/or recurrence of CHD 32, 33) . Statin therapy has been shown to reduce hS-CRP levels 34, 35) . The present study showed no association between elevated levels of hs-CRP and severe CHD among CHD patients treated with lipid-lowering drugs. On the other hand, increases in hs-CRP might be associated with an elevated risk for severe CHD among unmedicated CHD patients, although the odds ratio was not statistically significant. This suggests the atherogenicity of sd-LDL-C to be a more useful marker for severe CHD than hs-CRP, a non-lipid inflammatory marker, among stable CHD patients.
This study has a number of limitations. First, it is a cross-sectional study of patients referred for coronary angiography and could not show the progression or regression of coronary atherosclerosis. Second, our evaluation of coronary severity might be less precise than quantitative coronary arteriography (QCA) or the intravascular ultrasound (IVUS) technique, and angiography itself might be less accurate in measuring the severity of coronary lesions. These compromises in precision and accuracy are very likely, in fact, as coronary disease is well known to begin as intimal hyperplasia as an extraluminal process within the vessel wall. Prospective studies should be conducted to evaluate the relationship between changes of LDL-C and sd-LDL-C levels and the progression of CHD using QCA, IVUS, or the newly developed technique of ECG-gated multislice computed tomography.
In conclusion, sd-LDL particles and a high concentration of sd-LDL-C were both potent risk factors for CHD. For defining the severity of CHD using angiographic findings, our results indicated that a high sd-LDL-C concentration was closely related to the severity independently of classical coronary risk factors, whereas a high large-LDL-C concentration was not. This suggests that the measurement of sd-LDL-C using the precipitation method will be of more use than LDL-C as a surrogate marker to determine the severity of CHD, and that aggressive lipid-lowering therapy should be done in patients with higher sd-LDL-C levels compared to individuals with similar LDL-C levels.
